Skip to main content

Eli Lilly's weight loss drug slashes the risk of developing diabetes in long-term trial

The late-stage trial on tirzepatide also found that patients experienced sustained weight loss over the roughly three-year treatment period.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.